Antidepressant use in pregnant women linked to small increase in autism

A new study found that antidepressant medications taken during pregnancy may be linked to the development of autism in children - although the effect appears to be limited. In looking at a cohort of children born between 2001 and 2011 in Stockholm, Sweden, Drexel University's Brian Lee, PhD, and Craig Newschaffer, PhD, and their co-authors (including lead author Dheeraj Rai, PhD, of the University of Bristol) found that children born to mothers who had taken anti-depressants at any point during their pregnancy were 45 percent more likely to be diagnosed with autism. However, the team's analysis showed that only 2 percent of autism cases would be prevented if antidepressant use was completely cut off in pregnant women.

"Overall, the increase in risk was quite small," said Lee. "Of children exposed to antidepressants during pregnancy, 4.1 percent had an autism diagnosis. In comparison, children of mothers with a history of a psychiatric disorder but who did not use antidepressants during pregnancy had a 2.9 percent prevalence of autism."

The study was published in The BMJ (formerly The British Medical Journal). It focused on prenatal antidepressant use because these medications can cross through the placenta into where the fetus develops.

Past studies have found associations between antidepressant use during pregnancy and autism in children, but there has been some concern that those links were the results of other factors. As such, this study sought to use various methods to rule out any "confounders."

This included looking into the use of antidepressants by the child's father during pregnancy, comparing the children to their siblings, and comparing children with similar characteristics, among other methods.

None of these seemed to significantly affect the main finding linking diagnoses to antidepressant use.

"The overall effect remained," Rai said. "We were specifically looking for consistency in the various analyses we did and the results appeared to concur."

"We conducted several analyses that seemed to support the validity of the findings," Lee added. "For example, because a parental history of a psychiatric disorder is associated with increased risk of autism, we examined whether the father's use of antidepressants was associated with autism. Because there was no increased risk with fathers' use of antidepressants, this suggested that the increase with mothers' use was not entirely due to the underlying psychiatric disorder."

The team found that prenatal antidepressant use seemed to only be linked to autism diagnoses in children who didn't also have intellectual disabilities. This form of autism has a greater chance of inheritability, according to past studies. Genetic traits were not exclusively looked at for the study, although looking at siblings helped mitigate that potential factor. To better examine it in future studies, the study team suggested looking at larger pools of siblings.

And while there was a noticeable increase in autism diagnoses in children whose mothers used the antidepressants, the study team emphasized that more than 95 percent of those women had children who were not diagnosed with autism.

"Our advice for pregnant women and clinicians is very clear. They should not base decisions about the use of antidepressants during pregnancy on any one study, especially when the research evidence is conflicting, as in this case where different studies have reached different conclusions," Rai said. "There could be severe risks of stopping the use of antidepressants during pregnancy, both to the mother and the fetus. So the benefits of these medications for mothers who need them should not be forgotten."

The best course of action is to consult a doctor on medication use during pregnancy.

"Balancing benefits and risks of taking medications during pregnancy is a complex and often difficult decision," he explained. "Our advice would be for women to discuss their concerns with their treating clinicians who will be able to help them weigh the pros and the cons."

As a next step, larger studies will help develop a consensus on the role that both antidepressants and depression itself plays into the risk of autism.

"This may be aided by more studies that could help account for confounding and more studies focusing on the autism group without intellectual disability, which seems to be the key category for which the increase in risk is observed," Rai said.

Rai Dheeraj, Lee Brian K, Dalman Christina, Newschaffer Craig, Lewis Glyn, Magnusson Cecilia et al.
Antidepressants during pregnancy and autism in offspring: population based cohort study.
BMJ 2017; 358 :j2811, doi: 10.1136/bmj.j2811.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...